The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Open accessAbstract
This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials. The potential of peptides in cancer treatment is evident from a variety of different strategies that are available to address the progression of tumor growth and propagation of the disease. Use of peptides that can directly target cancer cells without affecting normal cells (targeted therapy) is evolving as an alternate strategy to conventional chemotherapy. Peptide can be utilized directly as a cytotoxic agent through various mechanisms or can act as a carrier of cytotoxic agents and radioisotopes by specifically targeting cancer cells. Peptide-based hormonal therapy has been extensively studied and utilized for the treatment of breast and prostate cancers. Tremendous amount of clinical data is currently available attesting to the efficiency of peptide-based cancer vaccines. Combination therapy is emerging as an important strategy to achieve synergistic effects in fighting cancer as a single method alone may not be efficient enough to yield positive results. Combining immunotherapy with conventional therapies such as radiation and chemotherapy or combining an anticancer peptide with a nonpeptidic cytotoxic drug is an example of this emerging field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2
Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200673200 · Cited by 1,696
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2069 · Cited by 1,388
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Anti-cancer activity of targeted pro-apoptotic peptides
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., et al. (1999) · Nature Medicine · doi:10.1038/12469 · Cited by 936
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 805
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
Grunnet, M., & Sorensen, J. B. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.012 · Cited by 750
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
The Nature of Selection on the Major Histocompatibility Complex
Apanius, V., Penn, D., Slev, P. R., Ruff, L. R., & Potts, W. K. (1997) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v17.i2.40 · Cited by 597
Vascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Classification and nomenclature of somatostatin receptors
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey, P. P. A., O'Carroll, A.-M., Patel, Y. C., Schonbrunn, A., Taylor, J. E., et al. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88988-9 · Cited by 570
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
The Nature of Selection on the Major Histocompatibility Complex
Apanius, V., Penn, D., Slev, P. R., Ruff, L. R., & Potts, W. K. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v37.i2-6.10 · Cited by 517
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., Schilling, T., Haufe, S., Herrmann, T., & Haberkorn, U. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0450-1 · Cited by 506
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
A tumor-homing peptide with a targeting specificity related to lymphatic vessels
Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002) · Nature Medicine · doi:10.1038/nm720 · Cited by 498
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Imaging of Neuroendocrine Tumors
Rufini, V., Calcagni, M. L., & Baum, R. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.03.007 · Cited by 376
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 346
Designing peptide receptor agonists and antagonists
Hruby, V. J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd939 · Cited by 344
Strategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature Reviews Immunology · doi:10.1038/35105075 · Cited by 334
Peptide receptor imaging and therapy.
Kwekkeboom, D. J., Krenning, E. P., & de Jong, M. (2000) · PubMed · Cited by 330
Imaging of Neuroendocrine Tumors
Heller, M. T., & Shah, A. B. (2011) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2011.02.011 · Cited by 329
Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis
Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K., Huang, P., Abbruzzese, J. L., & McConkey, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2370 · Cited by 309
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Peptide Science · doi:10.1002/bip.10257 · Cited by 308
Muderspach, L. I., Wilczynski, S. P., Roman, L. D., Bade, L., Felix, J. C., Small, L., Kast, W. M., Fascio, G., Marty, V., & Weber, J. S. (2000) · PubMed · Cited by 304
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
Miller, W. R., Scott, W. N., Morris, R. A., Fraser, H. M., & Sharpe, R. M. (1985) · Nature · doi:10.1038/313231a0 · Cited by 293
Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
Cescato, R., Maina, T., Nock, B., Nikolopoulou, A., Charalambidis, D., Piccand, V., & Reubi, J. C. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045054 · Cited by 293
Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062189599 · Cited by 291
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
Laakkonen, P., Åkerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., & Ruoslahti, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403317101 · Cited by 275
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
Schally, A., & Nagy, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410001 · Cited by 271
Zitzmann, S., Ehemann, V., & Schwab, M. (2002) · PubMed · Cited by 265
Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260
A proapoptotic peptide for the treatment of solid tumors.
Mai, J., Mi, Z., Kim, S.-H., Ng, B., & Robbins, P. D. (2001) · PubMed · Cited by 247
Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates
Zhang, X.-X., Eden, H. S., & Chen, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.023 · Cited by 243
Integrin Targeted Delivery of Chemotherapeutics
Chen, K., & Chen, X. (2011) · Theranostics · doi:10.7150/thno/v01p0189 · Cited by 242
Use of chlorotoxin for targeting of primary brain tumors.
Soroceanu, L., Gillespie, G. Y., Khazaeli, M. B., & Sontheimer, H. W. (1998) · PubMed · Cited by 237
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy
Cornelio, D. B., Roesler, R., & Schwartsmann, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm058 · Cited by 234
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
Krenning, E. P., de Jong, M., Kooij, P. P. M., Breeman, W. A. P., Bakker, W. H., de Herder, W. W., van Eijck, C. H. J., Kwekkeboom, D. J., Jamar, F., Pauwels, S., et al. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s23 · Cited by 234
DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
Otte, A., Jermann, E., Behe, M., Goetze, M., Bucher, H. C., Roser, H. W., Heppeler, A., Mueller-Brand, J., & Maecke, H. R. (1997) · European Journal of Nuclear Medicine · doi:10.1007/bf00879669 · Cited by 224
Ramanathan, R. K., Lee, K. M., McKolanis, J., Hitbold, E., Schraut, W., Moser, A. J., Warnick, E., Whiteside, T., Osborne, J., Kim, H., et al. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0581-1 · Cited by 217
Khalili, P., Arakelian, A., Chen, G., Plunkett, M. L., Beck, I., Parry, G. C., Doñate, F., Shaw, D. E., Mazar, A. P., & Rabbani, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0100 · Cited by 203
Zhang, H., Chen, J., Waldherr, C., Hinni, K., Waser, B., Reubi, J. C., & Maecke, H. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3845 · Cited by 201
Wild, D., Mäcke, H. R., Waser, B., Reubi, J. C., Ginj, M., Rasch, H., Müller-Brand, J., & Hofmann, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1697-4 · Cited by 192
Garanger, E., Boturyn, D., & Dumy, P. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668706 · Cited by 185
Chemotherapy targeted to cancers through tumoral hormone receptors
Schally, A. V., & Nagy, A. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.07.002 · Cited by 184
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Behe, M., Brink, I., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., & Weber, W. A. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 183
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
Grozinsky-Glasberg, S., Shimon, I., Korbonits, M., & Grossman, A. B. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0288 · Cited by 183
β-Peptides as inhibitors of protein–protein interactions
Kritzer, J. A., Stephens, O. M., Guarracino, D. A., Reznik, S. K., & Schepartz, A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.009 · Cited by 182
Esser, J. P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
Protein Transduction: Cell Penetrating Peptides and Their Therapeutic Applications
Wagstaff, K., & Jans, D. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776872871 · Cited by 176
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
Engel, J. B., & Schally, A. V. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0399 · Cited by 172
Anti-Angiogenic Peptides for Cancer Therapeutics
V. Rosca, E., E. Koskimaki, J., G. Rivera, C., B. Pandey, N., P. Tamiz, A., & S. Popel, A. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111796117300 · Cited by 170
NG2 proteoglycan-binding peptides target tumor neovasculature.
Burg, M. A., Pasqualini, R., Arap, W., Ruoslahti, E. I., & Stallcup, W. B. (1999) · PubMed · Cited by 166
Pauwels, S., Barone, R., Walrand, S., Borson‐Chazot, F., Valkema, R., Kvols, L. K., Krenning, E. P., & Jamar, F. (2005) · PubMed · Cited by 163
Gao, G. F., & Jakobsen, B. K. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01750-3 · Cited by 162
Current strategies for the development of peptide‐based anti‐cancer therapeutics
Borghouts, C., Kunz, C., & Groner, B. (2005) · Journal of Peptide Science · doi:10.1002/psc.717 · Cited by 161
van Essen, M., Krenning, E. P., Kooij, P. P. M., Bakker, W. H., Feelders, R. A., de Herder, W. W., Wolbers, J. G., & Kwekkeboom, D. J. (2006) · PubMed · Cited by 161
Broqua, P., Rivière, P. J.-M., Conn, P. M., Rivier, J., Aubert, M. L., & Junien, J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.95 · Cited by 152
Cho, H.-I., & Celis, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2019 · Cited by 147
Antitumor Peptides from Marine Organisms
Zheng, L.-H., Wang, Y.-J., Sheng, J., Wang, F., Zheng, Y., Lin, X.-K., & Sun, M. (2011) · Marine Drugs · doi:10.3390/md9101840 · Cited by 146
Sacchi, A., Gasparri, A. M., Gallo‐Stampino, C., Toma, S., Curnis, F., & Corti, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1147 · Cited by 144
Homing peptides as targeted delivery vehicles
Laakkonen, P., & Vuorinen, K. (2010) · Integrative Biology · doi:10.1039/c0ib00013b · Cited by 144
Alghisi, G. C., Ponsonnet, L., & Rüegg, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004449 · Cited by 140
Soto‐Pantoja, D. R., Menon, J., Gallagher, P. E., & Tallant, E. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0161 · Cited by 138
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Meyers, P. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.69 · Cited by 134
Hariharan, S., Gustafson, D. L., Holden, S. N., McConkey, D. J., Davis, D. W., Morrow, M., Basche, M., Gore, L., Zang, C., O’Bryant, C. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm140 · Cited by 130
A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors
Khleif, S. N., Abrams, S. I., Hamilton, J. M., Bergmann‐Leitner, E. S., Chen, A. P., Bastian, A., Bernstein, S. A., Chung, Y., Allegra, C. J., & Schlom, J. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199903000-00007 · Cited by 125
Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery
Li, Z. J., & Cho, C. H. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-s1-s1 · Cited by 120
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.
Yamamoto, K. T., Ueno, T., Kawaoka, T., Hazama, S., Fukui, M., Suehiro, Y., Hamanaka, Y., Ikematsu, Y., Imai, K., Oka, M., et al. (2005) · PubMed · Cited by 117
Function and expression of somatostatin receptors of the endocrine pancreas
Strowski, M. Z., & Blake, A. D. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.007 · Cited by 106
Experience with Indium-111 and Yttrium-90-Labeled Somatostatin Analogs
Virgolini, I. J., Traub‐Weidinger, T., Novotny, C., Leimer, M., Fueger, B. J., Li, S., Patri, P., Pangerl, T., Angelberger, P., Raderer, M., et al. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393756 · Cited by 97
Cardinale, D., Guaitoli, G., Tondi, D., Luciani, R., Henrich, S., Salo‐Ahen, O. M. H., Ferrari, S., Marverti, G., Guerrieri, D., Ligabue, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104829108 · Cited by 95
Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.
Hareuveni, M., Gautier, C., Kiény, M. P., Wreschner, D. H., Chambon, P., & Lathe, R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9498 · Cited by 94
Cancer Therapeutics- Opportunities, Challenges and Advances in Drug Delivery
Kakde, D. D., Kakde, R. B., Patil, A., Jain, D., & Shrivastava, V. (2011) · Cited by 92
Tonelli, R., Purgato, S., Camerin, C., Fronza, R., Bologna, F., Alboresi, S., Franzoni, M., Corradini, R., Sforza, S., Faccini, A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0213 · Cited by 91
Weber, J. S., Vogelzang, N. J., Ernstoff, M. S., Goodman, O. B., Cranmer, L. D., Marshall, J. L., Miles, S., Rosario, D., Diamond, D. C., Qiu, Z., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182280db1 · Cited by 87
Mutant ras epitopes as targets for cancer vaccines.
Abrams, S. I., Hand, P. H., Tsang, K.-Y., & Schlom, J. (1996) · PubMed · Cited by 86
Gregorc, V., Santoro, A., Bennicelli, E., Punt, C. J. A., Citterio, G., Timmer-Bonte, J. N. H., Cappio, F. C., Lambiase, A., Bordignon, C., & van Herpen, C. M. L. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605162 · Cited by 86
Peptide Inhibitors Targeting Protein Kinases
Eldar-Finkelman, H., & Eisenstein, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682253 · Cited by 82
Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies
Reff, M. E., Hariharan, K., & Braslawsky, G. R. (2002) · Cancer Control · doi:10.1177/107327480200900207 · Cited by 82
Prostate-Specific Membrane Antigen-Based Therapeutics
Akhtar, N. H., Pail, O., Saran, A., Tyrell, L., & Tagawa, S. T. (2011) · Advances in Urology · doi:10.1155/2012/973820 · Cited by 80
Lymphatic Zip Codes in Premalignant Lesions and Tumors
Zhang, L., Giraudo, E., Hoffman, J. A., Hanahan, D., & Ruoslahti, E. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3876 · Cited by 77
Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Mori, T. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383944 · Cited by 76
Receptor PET/CT Imaging of Neuroendocrine Tumors
Baum, R. P., Prasad, V., Hommann, M., & Hörsch, D. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31203-1_18 · Cited by 66
Gotthardt, M., Béhé, M. P., Grass, J., Bauhofer, A., Rinke, A., Schipper, M. L., Kalinowski, M., Arnold, R., Oyen, W. J. G., & Behr, T. M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01245 · Cited by 66
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.663.2.12 · Cited by 64
Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model.
Smolarczyk, R., Cichoń, T., Graja, K., Hucz, J., Sochanik, A., & Szala, S. (2006) · Acta Biochimica Polonica · doi:10.18388/abp.2006_3309 · Cited by 63
Gaviglio, L., Groß, A., Metzler‐Nolte, N., & Ravera, M. (2012) · Metallomics · doi:10.1039/c2mt00171c · Cited by 62
Treatment of Advanced Prostatic Cancer
Sogani, P. C., & Fair, W. R. (1987) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00575-9 · Cited by 62
Debruyne, F. M. J., Bhat, G., & Garnick, M. B. (2006) · Future Oncology · doi:10.2217/14796694.2.6.677 · Cited by 57
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z. Y., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · PubMed · Cited by 57
Gregorc, V., de Braud, F., Pas, T. M. D., Scalamogna, R., Citterio, G., Milani, A., Boselli, S., Catania, C., Donadoni, G., Rossoni, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1376 · Cited by 56
Hormonal therapy in prostate cancer: historical approaches.
Crawford, E. D. (2004) · Europe PMC (PubMed Central) · Cited by 54
Lee, T., Lin, Y., Seow, K., Hwang, J., Tzeng, C., & Yang, Y. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.06.029 · Cited by 51
Noy, A., Scadden, D. T., Lee, J. Y., Dezube, B. J., Aboulafia, D. M., Tulpule, A., Walmsley, S. L., & Gill, P. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.043 · Cited by 47
Park, K., Kim, Y.-S., Lee, G. Y., Park, R., Kim, I.-S., Kim, S. Y., & Byun, Y. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9643-y · Cited by 45
Santoro, A., Rimassa, L., Sobrero, A. F., Citterio, G., Sclafani, F., Carnaghi, C., Pessino, A. M., Caprioni, F., Andretta, V., Tronconi, M. C., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.012 · Cited by 44
Bajo, A. M., Schally, A. V., Krupa, M., Hébert, F., Groot, K., & Szepesházi, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052715299 · Cited by 43
Szepesházi, K., Schally, A. V., Halmos, G., Sun, B., Hébert, F., Csernus, B., & Nagy, A. (2001) · PubMed · Cited by 41
Hohla, F., Buchholz, S., Schally, A. V., Seitz, S., Rick, F. G., Szalontay, L., Varga, J. L., Zarándi, M., Halmos, G., Vidaurre, I., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9698 · Cited by 40
Therapeutic Cancer Vaccines in Combination with Conventional Therapy
Andersen, M. H., Junker, N., Ellebæk, E., Svane, I. M., & Straten, P. T. (2010) · BioMed Research International · doi:10.1155/2010/237623 · Cited by 38
Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer
Gjertsen, M. K., & Gaudernack, G. (1998) · Vox Sanguinis · doi:10.1111/j.1423-0410.1998.tb05462.x · Cited by 37
Foy, K. C., Miller, M. J., Moldovan, N. I., Carson, W. E., & Kaumaya, P. T. P. (2012) · OncoImmunology · doi:10.4161/onci.20708 · Cited by 36
Cancer vaccines and immunotherapies: emerging perspectives
HENDERSON, R., Mossman, S. P., Nairn, N. W., & Cheever, M. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.082 · Cited by 35
New Treatment Approaches for Prostate Cancer Based on Peptide Analogues
Stangelberger, A., Schally, A. V., & Djavan, B. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.021 · Cited by 35
Vaccines for Melanoma and Renal Cell Carcinoma
Kaufman, H. L. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.011 · Cited by 31
Rick, F. G., Buchholz, S., Schally, A. V., Szalontay, L., Krishan, A., Datz, C., Stadlmayr, A., Aigner, E. S., Perez, R., Seitz, S., et al. (2012) · Cell Cycle · doi:10.4161/cc.20900 · Cited by 30
GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
Nava-Parada, P., & Emens, L. A. (2007) · PubMed · Cited by 28
The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer
Retter, A. S., Figg, W. D., & Dahut, W. L. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.023 · Cited by 24
Novel anti‐angiogenic peptides derived From ELR‐containing CXC chemokines
Karagiannis, E. D., & Popel, A. S. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21712 · Cited by 23
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
Markowicz, S., Nowecki, Z. I., Rutkowski, P. L., Lipkowski, A. W., Biernacka, M., Jakubowska-Mućka, A., Świtaj, T., Misicka, A., Skurzak, H., Połowniak-Pracka, H., et al. (2012) · Medical Oncology · doi:10.1007/s12032-012-0168-1 · Cited by 20
Garetto, S., Sizzano, F., Brusa, D., Tizzani, A., Malavasi, F., & Matera, L. (2009) · Cytotherapy · doi:10.3109/14653240903164971 · Cited by 11
Yang, J. C. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325f72 · Cited by 11
Cited by
In Silico Approach for Predicting Toxicity of Peptides and Proteins
Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., Open Source Drug Discovery Consortium, & Raghava, G. P. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073957 · Cited by 2,012
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
iACP: a sequence-based tool for identifying anticancer peptides
Chen, W., Ding, H., Feng, P., Lin, H., & Chou, K.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.7815 · Cited by 433
CancerPPD: a database of anticancer peptides and proteins
Tyagi, A., Tuknait, A., Anand, P., Gupta, S., Sharma, M., Mathur, D., Joshi, A., Singh, S., Gautam, A., & Raghava, G. P. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku892 · Cited by 397
Peptides with Dual Antimicrobial and Anticancer Activities
Felício, M. R., Silva, O. N., Gonçalves, S., Santos, N. C., & Franco, O. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00005 · Cited by 393
Metadata
- Authors
- Thundimadathil, J.
- Venue
- Journal of Amino Acids
- Publisher
- Hindawi Limited
- Published
- 2012-12-20
- Volume
- 2012
- Pages
- 1-13
- ISSN
- 2090-0104 (ISSN-L)
- 2090-0112
- OpenAlex
- W2139709150
- Cited by
- 491
- References
- 131
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.